Multimodal Educative Data Feedback for Deprescribing BZD and Related Drugs in Outpatients: a Cluster RCT

Not Applicable

Completed

• Conditions: Deprescription; Benzodiazepine (BZD) and Related Drugs
• Interventions: Other: Thematic quality circles - Deprescription

• Registration Number: NCT05859555
• Lead Sponsor: Réseau de soins Delta

Brief Summary

Benzodiazepine (BZD) and related drugs are sedative anxiolytics and hypnotics that should be avoided especially in people aged 65 years and older, given the high risk of falling, fracture, dependence, respiratory depression and cognitive disorders. Despite these contraindications, their consumption continues to increase in Switzerland.

Although it can be assumed that deprescribing a drug has a direct benefit, it is nevertheless necessary to determine how to implement this process effectively and safely. To change healthcare professionals' prescribing behaviours for BZD, the most common deprescribing interventions include identification of appropriate patients, education and training of GPs and patients, and gradual and appropriate reduction of the dose of BZD. Thus, the DELTA CARE NETWORK and the DELTA VAUD CARE NETWORK have set themselves the task of evaluating the effectiveness of a multimodal deprescribing intervention for Delta primary care physicians and their patients aged 65 and over, in the cantons of Geneva and Vaud. The goal is to reduce the total BZD prescription rate among this population.

This quality development project is fully in line with the Quality Federal Commission's objectives of efficiency, safety, patient-centred and in the interests of the patient.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-12-05
• Study First Submitted: 2023-03-19
• Study First Submitted QC: 2023-05-11
• Study First Posted: 2023-05-16
• Primary Completion: 2024-05-21
• Study Completion: 2024-06-21
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-26
• Last Update Posted: 2024-11-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Physician who attended a quality cercle in the cantons of Geneva and Vaud
• Prescribed at least one prescription of Benzodiazepines during the year of analysis to patient aged 65 years and older

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention: Thematic quality circles - Deprescription	Thematic quality circles - Deprescription	-

Primary Outcome Measures

Name	Time	Method
Rate Benzodiazepine (BZD) and related drugs prescribed by primary care physicians	9 months	Reduce the total BZD prescribing frequency by 20% 9 months after the interventioncompared to the control group (DDD/1000 patients over 9 months). The drug measure will be the DDD daily dose defined by the World Health Organization Collaborating Centre for Drug Statistics Methodology (or number of tablets or number of packages).

Secondary Outcome Measures

Name	Time	Method
Rate of patients aged 65 years who took long-term BZD	18 months	Reduce by 20% the prevalence of 65-year-old patients with long-term use (more than 3 months) of BZD as well as the prevalence of long-term users 18 months after intervention (number of BDZ patients per physician/QC per year).

Trial Locations

Locations (1)

Réseau de soins Delta SA; 🇨🇭 Geneve, Petit Lancy, Switzerland